Bayesian Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bayesian Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,700	Closed	-$288K	–	373
2021 Q2	$288K	Buy	+1,700	New	+$249K	0.08%	285
2018 Q4	–	Sell	-5,000	Closed	-$438K	–	599
2018 Q3	$438K	Buy	+5,000	New	+$503K	0.07%	359

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bayesian Capital Management's ALNY Position: Q3 2021 in Review

Bayesian Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2021, closing a stake of 1,700 shares — an estimated $288K sold.

Bayesian Capital Management first reported a position in ALNY in Q3 2018 and held it in 2 quarters. The position peaked at $438K in Q3 2018. 405 funds tracked by Wall St. Rank hold ALNY as of Q3 2021.

Bayesian Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Bayesian Capital Management sold 1,700 Alnylam Pharmaceuticals shares in Q3 2021, an estimated $288K.
Bayesian Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2018 and held it in 2 quarters.
Bayesian Capital Management's Alnylam Pharmaceuticals position peaked at $438K in Q3 2018.
405 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2021.

Based on Bayesian Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.